Evaluation of the safety of FMT and recurrence of clinical symptoms of CDAD will be performed by the primary physicians and research coordinators from the EPDL-UT-SPH. The primary endpoint is to evaluate the safety of the FMT (fresh or frozen or lyophilized health donor feces) for the treatment of patients with 3 or more episodes of RCDAD. A second efficacy endpoint is to evaluate the recurrence of clinical symptoms and CDAD after initial therapy. In order to monitor any health effects for safety, participants will be contacted quarterly for three years following study completion. The recipient will be contacted by the investigator pre- and approximately 7, 14 and 30 days after the procedure is performed. The following procedures will be completed: review recipient diary with the recipient to ensure that the following information is recorded correctly and a fresh stool sample will be collected from recipient, tested for C. difficile toxins and an aliquot (2 mL) stored at -80C for future analysis (e.g. microbiome). The recipients will be contacted by phone for their diarrhea status.